Alector (ALEC)
(Delayed Data from NSDQ)
$5.31 USD
+0.24 (4.73%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $5.30 -0.01 (-0.19%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Alector (ALEC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.75 | $35.00 | $4.00 | 171.20% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Alector comes to $13.75. The forecasts range from a low of $4.00 to a high of $35.00. The average price target represents an increase of 171.2% from the last closing price of $5.07.
Analyst Price Targets (8 )
Broker Rating
Alector currently has an average brokerage recommendation (ABR) of 1.73 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.73 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, eight are Strong Buy, representing 72.73% of all recommendations. A month ago, Strong Buy represented 72.73%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ALEC.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.73 | 1.73 | 1.73 | 1.73 | 1.73 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/8/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
6/30/2024 | Goldman Sachs | Corinne Johnson | Strong Sell | Strong Sell |
5/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | Cantor Fitzgerald & Co | Pete Stavropoulos | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Thomas Shrader | Strong Buy | Strong Buy |
11/17/2023 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.73 |
ABR (Last week) | 1.73 |
# of Recs in ABR | 11 |
Average Target Price | $13.75 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.53 |